Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2024-02-07

Clinical Trial Update: Long-term Safety and Efficacy of GSK3196165 (Otilimab) in the Treatment of Rheumatoid Arthritis (RA) [Phase 3]

View source ↗

Summary

Phase 3 trial update for otilimab (GSK3196165) in rheumatoid arthritis shows termination with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • GSK3196165 (GSK3196165)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Arthritis, Rheumatoid | Phase 3 | Status: TERMINATED | Results posted: 2024-02-07